Keyword: InFLAMES Flagship

This page displays contents related to the keyword.

New and crucial role discovered for a protein in the body's immunity against cancer


Researchers at the University of Turku in Finland have found a new function for an existing protein. They discovered that TIMP-1, a protein traditionally known to prevent damage to the body's cells and tissues, plays a critical role in the immune system's defence against cancer. The findings of the study could improve the effectiveness of current cancer immunotherapies.

Scientists discover a novel modulator of human regulatory T cells


The research group of Professor Riitta Lahesmaa have discovered a novel modulator for human regulatory T cells. This novel regulator can strengthen or dampen immune response and provides a new basis for therapeutic approaches for immune mediated diseases. The Lahesmaa group is based at Turku Bioscience Centre of the University of Turku and Åbo Akademi University and is part of the InFLAMES Research Flagship.

Sirpa and Markku Jalkanen nominated for the European Inventor Award


Academician and Director of InFLAMES Flagship Sirpa Jalkanen and Dr. Markku Jalkanen have been nominated for the European Inventor Award. They are finalists in the Small and medium enterprises category, where they are against two other European teams. They were selected from among more than 550 candidates in a competition organised by the European Patent Office (EPO). The winners of the European Inventor Award 2024 will be announced on 9 July 2024 in Malta.

Europe’s main computational biology conference comes to Turku, Finland


Discoveries made when biology meets computational sciences are revolutionising the landscape of life sciences and healthcare. Computational biology and bioinformatics are driving this transformation, helping researchers analyse vast amounts of biological data. European Conference on Computational Biology (ECCB) is Europe’s main event in computational biology and bioinformatics this year, bringing 600–800 experts to Turku, Finland, on 16–20 September 2024.

Johanna Ivaska and Lauri Nummenmaa receive €2.5 million in EU funding for cancer research and research in negative emotions


University of Turku Professors Johanna Ivaska and Lauri Nummenmaa have received significant research funding from the European Research Council ERC. Ivaska received funding for a project that aims to discover how the biological limits of a healthy body influence cancer progression. Nummenmaa’s project examines the link between a person’s negative emotions and their physical well-being.

Alexander Mildner found his passion in macrophages


Young Alexander Mildner wanted to be an artist. His parents did not object to the idea but suggested that their son should first go to the University of Göttingen, from where he could transfer to an art school after a year. But things turned out differently. Today, Mildner is one of the world's most cited immunology researchers and an Associate Professor at the InFLAMES flagship of the University of Turku.  

New drug developed for melanoma and lung cancer shows potential in treatment of cutaneous squamous cell carcinoma


Cutaneous squamous cell carcinoma (cSCC), also known as the squamous cell carcinoma of the skin, is the most common form of metastatic skin cancer. The incidence of cSCC is increasing worldwide with millions of new cases diagnosed each year. The prognosis of metastatic cSCC is poor as there are currently no effective targeted treatments available. New study conducted at the University of Turku, Finland, shows that plixorafenib, a new drug developed for treating melanoma and lung cancer, can also stop the progression of cutaneous squamous cell carcinoma.

Unlocking the secrets of cell behaviour on soft substrates: A paradigm shift in mechanobiology


A research group from the University of Turku and Turku Bioscience Centre together with Misvik Biology Ltd in Finland have developed a new method for studying how cancer cells function in softer and stiffer tissue environments. This insight challenges the existing paradigm, opening up new possibilities for research in cancer biology and tissue engineering.